Dimerix Limited (AU:DXB) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dimerix Limited has announced the commencement of adolescent patient recruitment for their ACTION3 Phase 3 global clinical trial for FSGS, a leading cause of kidney failure in children. The approved DMX-200 dose for adolescents will match the adult dosage, based on positive safety and pharmacokinetic data, paving the way for addressing this high-need pediatric condition. Approximately 15 specialist centres internationally are set to participate in this crucial trial.
For further insights into AU:DXB stock, check out TipRanks’ Stock Analysis page.